A detailed history of Cwm, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 2,153 shares of ARWR stock, worth $42,263. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,153
Previous 80,169 97.31%
Holding current value
$42,263
Previous $2.08 Million 97.98%
% of portfolio
0.0%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$19.36 - $29.54 $1.51 Million - $2.3 Million
-78,016 Reduced 97.31%
2,153 $42,000
Q2 2024

Jul 09, 2024

SELL
$21.87 - $28.24 $419,335 - $541,473
-19,174 Reduced 19.3%
80,169 $2.08 Million
Q1 2024

Apr 05, 2024

SELL
$27.21 - $39.48 $99,887 - $144,931
-3,671 Reduced 3.56%
99,343 $2.84 Million
Q4 2023

Feb 01, 2024

SELL
$21.2 - $31.03 $120,903 - $176,964
-5,703 Reduced 5.25%
103,014 $3.15 Million
Q3 2023

Oct 11, 2023

SELL
$26.2 - $36.08 $111,481 - $153,520
-4,255 Reduced 3.77%
108,717 $2.92 Million
Q2 2023

Aug 03, 2023

BUY
$25.16 - $41.38 $668,627 - $1.1 Million
26,575 Added 30.76%
112,972 $4.03 Million
Q1 2023

Apr 28, 2023

SELL
$23.68 - $38.51 $95,288 - $154,964
-4,024 Reduced 4.45%
86,397 $2.19 Million
Q4 2022

Feb 01, 2023

SELL
$28.0 - $40.56 $497,252 - $720,305
-17,759 Reduced 16.42%
90,421 $3.67 Million
Q3 2022

Oct 27, 2022

SELL
$29.63 - $48.31 $122,668 - $200,003
-4,140 Reduced 3.69%
108,180 $3.58 Million
Q2 2022

Jul 28, 2022

SELL
$27.79 - $50.61 $452,921 - $824,841
-16,298 Reduced 12.67%
112,320 $3.96 Million
Q1 2022

Apr 21, 2022

SELL
$39.62 - $69.97 $805,236 - $1.42 Million
-20,324 Reduced 13.65%
128,618 $5.92 Million
Q4 2021

Jan 31, 2022

BUY
$58.09 - $82.51 $3.88 Million - $5.51 Million
66,746 Added 81.2%
148,942 $9.88 Million
Q1 2021

Sep 15, 2021

BUY
$61.35 - $90.47 $1.32 Million - $1.95 Million
21,508 Added 35.44%
82,196 $6.81 Million
Q1 2021

Apr 27, 2021

SELL
$61.35 - $90.47 $1.32 Million - $1.95 Million
-21,508 Reduced 26.17%
60,688 $4.02 Million
Q4 2020

Sep 15, 2021

BUY
$43.82 - $85.37 $940,815 - $1.83 Million
21,470 Added 35.36%
82,196 $6.81 Million
Q4 2020

Jan 27, 2021

SELL
$43.82 - $85.37 $940,815 - $1.83 Million
-21,470 Reduced 26.12%
60,726 $4.66 Million
Q3 2020

Sep 15, 2021

BUY
$33.21 - $51.27 $2.71 Million - $4.18 Million
81,586 Added 13374.75%
82,196 $6.81 Million
Q3 2020

Oct 19, 2020

SELL
$33.21 - $51.27 $2.71 Million - $4.18 Million
-81,586 Reduced 99.26%
610 $26,000
Q2 2020

Sep 15, 2021

BUY
$26.12 - $43.27 $2.13 Million - $3.53 Million
81,586 Added 13374.75%
82,196 $6.81 Million
Q2 2020

Jul 22, 2020

SELL
$26.12 - $43.27 $2.13 Million - $3.53 Million
-81,586 Reduced 99.26%
610 $26,000
Q1 2020

Sep 15, 2021

BUY
$20.56 - $63.12 $1.68 Million - $5.16 Million
81,786 Added 19947.8%
82,196 $6.81 Million
Q1 2020

Apr 28, 2020

SELL
$20.56 - $63.12 $1.68 Million - $5.16 Million
-81,786 Reduced 99.5%
410 $12,000
Q4 2019

Sep 14, 2021

BUY
$28.14 - $73.01 $2.31 Million - $6 Million
82,136 Added 136893.33%
82,196 $6.81 Million
Q4 2019

Jan 27, 2020

SELL
$28.14 - $73.01 $2.31 Million - $6 Million
-82,136 Reduced 99.93%
60 $4,000
Q3 2019

Sep 14, 2021

BUY
$26.26 - $34.86 $2.16 Million - $2.86 Million
82,136 Added 136893.33%
82,196 $6.81 Million
Q3 2019

Oct 22, 2019

SELL
$26.26 - $34.86 $2.16 Million - $2.86 Million
-82,136 Reduced 99.93%
60 $2,000
Q2 2019

Sep 14, 2021

BUY
$17.43 - $28.82 $1.43 Million - $2.37 Million
82,136 Added 136893.33%
82,196 $6.81 Million
Q2 2019

Jul 31, 2019

SELL
$17.43 - $28.82 $1.43 Million - $2.37 Million
-82,136 Reduced 99.93%
60 $2,000
Q1 2019

Sep 02, 2021

BUY
$12.05 - $20.18 $989,509 - $1.66 Million
82,117 Added 103945.57%
82,196 $0
Q1 2019

Apr 22, 2019

BUY
$12.05 - $20.18 $228 - $383
19 Added 31.67%
79 $1,000
Q3 2017

Oct 16, 2017

BUY
$1.69 - $4.33 $101 - $259
60
60 $0

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.